Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
balicatib · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| balicatib (AAE581) | DRUG | - |
Inclusion Criteria: * At least one knee with osteoarthritis with Kellgren-Lawrence grade 3 * Significant osteoarthritis pain in the knee * Presence of at least one of the risk factors: obesity (BMI \> 28), osteoarthritis at other sites, knee effusion, family history of total joint replacement Excl...
Balicatib is an investigational small molecule being studied for the treatment of knee osteoarthritis, a degenerative joint disease. It is being developed by Novartis AG as a potential therapy for this condition, which affects the cartilage and surrounding tissues in the knee joint.
Balicatib is a small molecule that targets cathepsin K, an enzyme involved in bone and cartilage remodeling. By inhibiting this enzyme, balicatib aims to slow the breakdown of cartilage in the knee joint, which is a key feature of osteoarthritis.
Balicatib is being developed by Novartis AG, a multinational pharmaceutical company headquartered in Switzerland. Novartis is listed on the New York Stock Exchange under the ticker symbol NVS.
Balicatib is in Phase 2 clinical development. It has completed a Phase 2 trial, but it is still considered investigational and has not been approved by regulatory authorities. The drug is not yet available for commercial use.
Balicatib has been studied in one completed Phase 2 clinical trial with the identifier NCT00371670. This trial, titled 'Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee,' enrolled 223 participants in the United States and Germany.
Yes, balicatib is also known as AAE581. In clinical trial records, it is sometimes referred to by this alternative name, which is the compound designation used by the developer, Novartis.